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The mechanisms by which neutralizing antibodies
inhibit Marburg virus (MARV) are not known. We iso-
lated a panel of neutralizing antibodies from a human
MARV survivor that bind to MARV glycoprotein (GP)
and compete for binding to a single major antigenic
site. Remarkably, several of the antibodies also
bind to Ebola virus (EBOV) GP. Single-particle EM
structures of antibody-GP complexes reveal that all
of the neutralizing antibodies bind to MARV GP at
or near the predicted region of the receptor-binding
site. The presence of the glycan cap or mucin-like
domain blocks binding of neutralizing antibodies to
EBOV GP, but not to MARV GP. The data suggest
that MARV-neutralizing antibodies inhibit virus by
binding to infectious virions at the exposedMARV re-
ceptor-binding site, revealing a mechanism of filovi-
rus inhibition.INTRODUCTION
Marburg virus (MARV) and Ebola virus (EBOV), which are mem-
bers of the family Filoviridae, infect humans and non-human pri-
mates, causing a hemorrhagic fever with mortality rates up to
90% (Brauburger et al., 2012). There have been a dozen out-
breaks of Marburg virus infection in humans reported to date,
including the most recent report from Uganda of a 30-year-old
male health worker who died in September 2014 (WHO,
2014a). As of January 7, 2015, there have been in excess of
20,000 confirmed, probable, and suspected cases of Ebola virus
disease (EVD) in the current EBOV outbreak in nine affected
countries (Guinea, Liberia, Mali, Nigeria, Senegal, Sierra Leone,Spain, the United Kingdom, and the United States of America),
with more than 8,000 deaths (WHO, 2014b).
There is no licensed treatment or vaccine for filovirus infection.
Recently, several studies showed that filovirus glycoprotein
(GP)-specific neutralizing antibodies (nAbs) can reduce mortality
following experimental inoculation of animals with a lethal dose
of EBOV (Dye et al., 2012; Marzi et al., 2012; Olinger et al.,
2012; Qiu et al., 2012, 2014; Pettitt et al., 2013) or MARV (Dye
et al., 2012). The primary target of these nAbs, the filovirus sur-
face GP, is a trimer composed of three heavily glycosylated
GP1-GP2 heterodimers (Figure S1). The GP1 subunit can be
divided further into base, head, glycan cap, and mucin-like do-
mains (Lee et al., 2008). During viral entry, the mucin-like domain
and glycan capmediate binding to multiple host attachment fac-
tors present on the cell membrane. After the virus enters the host
cell by macropinocytosis (Nanbo et al., 2010; Saeed et al., 2010),
the GP is cleaved by host proteases that remove approximately
80% of the mass of the GP1 subunit, including the mucin-like
domain and glycan cap (Chandran et al., 2005; Dube et al.,
2009). After cleavage of GP in the endosome, the receptor-bind-
ing sites on GP become exposed, and the GP1 head then is able
to bind to its receptor, Niemann-Pick C1 (NPC1) protein (Carette
et al., 2011; Chandran et al., 2005; Coˆte´ et al., 2011). Subsequent
conformational changes in GP facilitate fusion between viral and
endosomal membranes.
The dense clustering of glycans on the glycan cap and mucin-
like domain likely shield much of the surface of EBOV GP from
humoral immune surveillance, leaving only a few sites on the
EBOV GP protein at which nAbs could bind without interference
by glycans (Cook and Lee, 2013). Most of our knowledge about
humoral response against filovirus infections has come from
studies of murine Abs that recognize EBOV GP. From those
studies, we learned that mouse nAbs preferentially target pep-
tides exposed in upper, heavily glycosylated domains or lower
areas (the GP1 base), where rearrangements occur that driveCell 160, 893–903, February 26, 2015 ª2015 Elsevier Inc. 893
fusion of viral and host membranes (Saphire, 2013). Abs have not
been identified that target protein features of the GP1 head sub-
domain, where the receptor-binding site to NPC1 protein is
located. Ab KZ52, the only reported human EBOV GP-specific
mAb, was obtained from a phage display library that was con-
structed from bone marrow RNA obtained from a survivor
(Maruyama et al., 1999). KZ52 binds a site at the base of the
GP and neutralizes EBOV,most likely by inhibiting the conforma-
tional changes required for fusion of viral and endosomal mem-
branes (Lee et al., 2008). Some murine Abs also have been
reported to bind to the base region of Ebola virus GPs (Dias
et al., 2011, Murin et al., 2014). In contrast, very little is known
about the mechanisms by which Abs neutralize MARV. Two mu-
rine Abs that bound the mucin-like domain of MARV GP reduced
MARV budding from infected cells in culture but failed to
neutralize virus directly (Kajihara et al., 2012). Polyclonal
MARV-specific Abs were shown to protect non-human primates
when administrated passively after challenge (Dye et al., 2012).
The epitopes recognized by such polyclonal nAbs, and the
mechanism of neutralization by which these Abs act, are un-
known. In this study, we isolated a large panel of human nAbs
from B cells of a human survivor of severe MARV infection and
used these Abs to define the molecular basis of MARV neutrali-
zation by human Abs. The results show that MARV nAbs recog-
nize the NPC1 receptor-binding domain of MARV GP and, in
some cases, also recognize conserved structural features in
the equivalent receptor-binding domain on EBOV GP.
RESULTS
Isolation of Monoclonal Antibodies
We tested plasma of a MARV survivor previously infected in
Uganda for the 50% neutralization activity against the Uganda
strain of MARV and found a serum-neutralizing titer of 1:1,010.
To generate human hybridoma cell lines secreting mAbs to
MARV, we screened supernatants from EBV-transformed B
cell lines derived from the survivor for binding to several recom-
binant forms of MARV GP or to irradiated cell lysates prepared
from MARV-infected cell cultures. We fused transformed cells
from B cell lines producing MARV-reactive Abs to the MARV
antigens with myeloma cells and generated 51 cloned hybrid-
omas secreting MARV-specific human mAbs. Thirty-nine of
these mAbs were specific to the MARVGP, while 12 bound to in-
fected-cell lysate, but not to GP; these latter mAbs were shown
in secondary screens to bind to MARV internal proteins (NP,
VP35, or VP40; data not shown). Analysis of the Ab heavy- and
light-chain variable domain sequences revealed that all MARV-
specific mAbs were encoded by unique Ab genes.
Neutralization Activity
To evaluate the inhibitory activity of themAbs, we first performed
in vitro neutralization studies using a chimeric vesicular stomati-
tis virus with MARV GP from Uganda strain on its surface (vesic-
ular stomatitis virus/Marburg glycoprotein recombinant VSV/
GP-Uganda). Eighteen of the 39 MARV GP-specific mAbs ex-
hibited neutralization activity against VSV/GP-Uganda (Figures
1A and 1C; Figures S2 and S4). Of those 18 nAbs, 9 displayed
strong (IC50 < 10 mg/ml), 8 nAbs displayed moderate (IC50: 10–894 Cell 160, 893–903, February 26, 2015 ª2015 Elsevier Inc.99 mg/ml), and one displayed weak (IC50: 100–1,000 mg/ml)
neutralizing activity against VSV/GP-Uganda. We also tested
the neutralization potency of all nAbs that bound to MARV GP
in a plaque reduction assay using live MARV-Uganda virus. Of
18 Abs that neutralized VSV/GP-Uganda, 11 Abs exhibited
neutralizing activity against MARV-Uganda (Figures 1A and 1C;
Figures S3 and S4). These data suggest that VSV/GP, often
used to study neutralizing potency of Abs because of its BSL-2
containment level, is more susceptible to Ab-mediated neutrali-
zation than live MARV. This difference is likely explained by the
significantly lower copy number of MARV GP molecules that
incorporate into VSV particles compared with the large number
of GP molecules on the surface of filovirus filaments (Beniac
et al., 2012; Thomas et al., 1985). Comparison of MARV-neutral-
izing and non-neutralizing antibodies at concentration up to
1.6 mg/ml revealed dose-dependent activity of those mAbs
that neutralized. The neutralization activity of nAbs was not
enhanced by the presence of complement (data not shown).
As expected, we did not detect neutralizing activity for any of
the 12 Abs specific to MARV NP, VP35, or VP40 proteins.
Recognition of Varying Forms of GP
To characterize the binding of isolated Abs to recombinant
MARV GPs, we performed binding assays using either a recom-
binant MARV GP ectodomain containing the mucin-like domain
(MARVGP) or a recombinant GP lacking residues 257–425 of the
mucin-like domain (MARV GPDmuc). Based on OD405 values at
the highest Ab concentration tested (Emax) and 50% effective
concentration (EC50), we divided the MARV-GP-specific Abs
into four major groups, based on binding phenotype (designated
binding groups 1, 2, 3A, and 3B; Figures 1B and S5). Binding
group 1 mAbs had an Emax to GP <2 (i.e., these mAbs never ex-
hibited a maximal binding level to MARV GP); binding group 2
mAbs had an Emax to GP >2, with EC50 for GP <EC50 for GPDmuc
(i.e., these mAbs bound to the mucin-like domain or glycan cap);
and binding group 3 had an Emax to GP >2, with EC50 for
GPzEC50 for GPDmuc (i.e., these mAbs bound equally well to
full-length and mucin-deleted forms of GP), with the group 3A
mAbs having an EC50 for GP <0.5 mg/ml and the group 3B
mAbs having an EC50 for GP >0.5 mg/ml (suggesting that, as a
class, the group 3B mAbs possess a lower steady-state KD of
binding to GP than did group 3A mAbs).
Abs that lacked neutralization activity against VSV/GP-
Uganda or MARV-Uganda fell principally into binding groups 1,
2, and 3A. Interestingly, all VSV/GP-Uganda nAbs displayed a
unique binding pattern and segregated into binding group 3B
(Figure 1C). It was interesting that while both mAbs from groups
3A and 3B bound equally well to the full-length MARV GP and to
the GPDmuc, EC50 values for nAbs from binding group 3B were
higher than those for non-neutralizing Abs from group 3A.
Competition-Binding Studies
To determine whether mAbs from distinct binding groups tar-
geted different antigenic regions on the MARV GP surface, we
performed a competition-binding assay using a real-time
biosensor. We tested 18 MARV nAbs from binding group 3B, 4
Abs from binding group 3A, and 1 Ab from binding group 2 in a
tandem blocking assay in which biotinylated GPDmuc was
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Figure 1. MARV-Neutralizing mAbs Display a Unique Binding Pattern and Target a Distinct Antigenic Region on the GP Surface
(A) Neutralization activity of MR77 (non-neutralizing antibody) or MR213 (neutralizing antibody) against VSV/GP-Uganda (red circles) or MARV-Uganda (black
circles). Error bars represent the SE of the experiment performed in triplicate.
(B) Binding of representative mAbs from four distinct binding groups to the MARV GP (blue squares) or MARV GPDmuc (green squares). A dotted line indicates
0.5 mg/ml threshold for categorizing group 3 antibodies as possessing low (3A) or high (3B) EC50 values.
(C) Heatmap showing the neutralization potency of MARV GP-specific mAbs against VSV/GP-Uganda or MARV-Uganda. The IC50 value for each virus-mAb
combination is shown, with dark red, orange, yellow, or white shading indicating high, intermediate, low, or no potency, respectively. IC50 values greater than
1,000 mg/ml are indicated by >. Neutralization assays were performed in triplicate.
(D) Data from competition binding assays using mAbs from binding groups 2, 3A, or 3B. Numbers indicate the percent binding of the competing mAb in the
presence of the first mAb, compared to binding of competing mAb alone. MAbs were judged to compete for the same site if maximum binding of the competing
mAb was reduced to <30% of its un-competed binding (black boxes with white numbers). MAbs were considered non-competing if maximum binding of the
competing mAb was >70% of its un-competed binding (white boxes with red numbers). Gray boxes with black numbers indicate an intermediate phenotype
(between 30 and 70% of un-competed binding).
See also Figures S2, S3, S4, and S5.attached to a streptavidin biosensor. Abs from group 1 and the
two non-neutralizing Abs from binding group 3B did not bind
to biotinylated GPDmuc in the competition assay and were
excluded from the analysis. While non-neutralizing Abs frombinding groups 2 and 3A did not prevent binding of the binding
group 3B nAbs to GPDmuc, all nAbs blocked binding of each
of the other nAbs to the antigen and segregated into a single
competition-binding group (Figure 1D). These data suggestedCell 160, 893–903, February 26, 2015 ª2015 Elsevier Inc. 895
A B C D
Figure 2. Neutralizing Antibodies from a Human Survivor of MARV Bind to the Receptor-Binding Site of GP at Two Distinct Angles of
Approach
(A) Representative reference-free 2D class averages of the MARV GPDMuc:MR Fab complexes.
(B) EM reconstructions of seven Fab fragments of neutralizing antibodies bound to MARV GPDmuc (side views). All seven antibodies target a similar epitope on
the top of GP.
(C) These antibodies can be subdivided based on their angles of approach: (1) those that bind toward the top and side of GP1 at a shallow angle relative to the
central 3-fold axis (MR72 in red, MR78 in orange, MR201 in yellow, or MR82 in green) and (2) those that bind at a steeper angle toward the top of GP1 (MR191 in
cyan, MR111 in blue, or MR198 in purple).
(D) The crystal structure of EBOV GPDmuc (GP1 in white and GP2 in dark gray) is modeled into the MARV GP density (mesh), and the angles of approach of the
neutralizing antibodies are indicated with arrows, colored as in (B). The footprint of the antibodies is indicated by a black circle targeting residues in the putative
receptor-binding site (RBS) through a variety of approach angles.
See also Figure S1.that all of the nAbs target a single major antigenic region on the
MARV GP surface.
Electron Microscopy Studies of Antigen-Antibody
Complexes
To determine the location of the antigenic region targeted by
MARV nAbs, we performed negative stain single-particle elec-
tron microscopy (EM) studies using complexes of GPDmuc
with Fab fragments of seven nAbs from Binding Group 3B. The
EM reconstructions clearly showed that Fab fragments for all
seven nAbs bind at the top of the GP in or near the NPC1 protein
receptor-binding site (Figures 2A and 2B). The binding pattern of
these Abs could be divided further into two major groups based
on their relative angle of approach to the GP head domain. MAbs
MR72, MR78, MR201, andMR82 bound toward the top and side
of GP1 at a shallow angle relative to the central 3-fold axis, while896 Cell 160, 893–903, February 26, 2015 ª2015 Elsevier Inc.mAbs MR191, MR111, and MR198 bound at a steeper angle
toward the top of GP1 (Figures 2C and 2D). When we compared
IC50 values for nAbs that bound in the two binding poses, we did
not detect a significant difference in neutralization potency
based on the angle of approach (Figure 1C).
Antibody Neutralization Escape Mutant Viruses
As an additional strategy to determine residues on MARV GP
involved in binding to nAbs, we generated VSV/GP-Uganda
variant viruses that escaped neutralization, and then we deter-
mined the sequence of the GP of those mAb escape viruses.
Vero E6 cells were inoculated with VSV/GP-Uganda in the pres-
ence of MR72 or MR78 nAbs. Two escape mutant viruses were
isolated: virus variant VSV/GP-72.5 contained three missense
mutations in the MARV GP gene (N129S in the putative NPC1 re-
ceptor-binding site, S220P in the glycan cap and P455L in the
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Figure 3. Generation of Escape Mutants for
MARV-Neutralizing Antibodies
(A) VSV-MARV-72.5 (dotted lines) or VSV-MARV-
78.1 (dashed line) escape mutations mapped onto
the domain schematic of MARV GP. RBS, receptor
binding site; GLC, glycan cap; MUC, mucin-like
domain.
(B) Neutralization activity of antibodies from bind-
ing group 3B against wild-type VSV/GP-Uganda
(circles, straight curves), VSV/GP-72.5 (squares,
dotted curves), or VSV/GP-78.1 (triangles, dashed
curves) escape mutant viruses.mucin-like domain), and virus variant VSV/GP-78.1 possessed
missense mutation C226Y in the glycan cap (Figure 3A). Consis-
tent with the EM data, six out of seven nAbs tested displayed a
higher level of neutralization activity against the wild-type VSV/
GP-Uganda than to the VSV/GP-72.5 or VSV/GP-78.1 escape
mutant viruses, suggesting these nAbs recognize MARV GP in
a similar fashion (Figure 3B). MAb MR198 exhibited equal
neutralization potency against wild-type VSV/GP-Uganda or
the two escape mutant viruses (Figure 3B). As all nAbs segre-
gated into one competition group (Figure 1D), bound the
MARV GP at the NPC1 receptor-binding site (Figures 2A–2D),
and displayed a similar profile of neutralization of escape mutant
viruses (Figure 3B), we propose that blocking of MARV GP bind-
ing to NPC1 is the principal mechanism of MARV neutralization
by these naturally occurring human Abs. Thismodel is supported
by the data in the accompanying paper by Hashiguchi et al.
(2015; this issue of Cell) showing that MR78 inhibits binding of
NPC1 domain C to MARV GP.
Cross-Reactive Binding of MARV Antibodies with
EBOV GP
It is surprising that human MARV nAbs recognize the putative
NPC1 protein receptor-binding site on GP, since previous
studies suggested that the NPC1 protein receptor-binding site
on EBOV GP may be obscured from Ab binding by the presence
of the highly glycosylated glycan cap and mucin-like domainCell 160, 893–903,(Lee et al., 2008). To determine whether
the MARV nAbs we isolated also could
bind in a cross-reactive manner to the
EBOV GP receptor-binding site, we per-
formed ELISA using three recombinant
forms of MARV and EBOVGPs: full-length
GP ectodomain containing the glycan
cap and mucin-like domain (designated
MARV or EBOV GP), ectodomains lacking
residues 257–425 (MARV) or 314–462
(EBOV) of the mucin-like domain (desig-
nated MARV or EBOV GPDmuc), and
cleaved GP ectodomains enzymatically
treated to remove the mucin-like domain
and glycan cap (designated MARV or
EBOV GPcl). Three of the MARV nAbs,
designated MR78, MR111, and MR191,
recognized the EBOV GPcl that lackedthe glycan cap and mucin-like domain (Figure 4A). Remarkably,
the MARV nAb MR72 bound all three forms of both EBOV and
MARV GPs with similar EC50 and Emax values, indicating that
its epitope, and the EBOV receptor-binding site, which it likely
overlaps, might be partially accessible for Ab binding even in
the full-length form (Figure 4A). We tested the breadth of neutral-
ization of MARV nAbs for filoviruses using a panel of different
MARV and EBOV isolates. While multiple MARV Abs displayed
neutralizing activity toward different MARV strains, MARV nAbs
did not exhibit detectable neutralization activity against EBOV
or VSV/EBOV (Figure 4B). Structural analysis of MARV and
EBOV GP in the accompanying paper by Hashiguchi et al.
(2015) reveals that the glycan cap and mucin-like domain likely
obscure the receptor-binding domain in EBOV, but not in MARV.
In Vivo Testing
We tested the in vivo protective activity of the mAbs in a murine
model using mouse-adapted MARV strain Ci67 (Warfield et al.,
2007, 2009). Inoculation of mice with MARV Ci67 causes clinical
disease and, in a proportion of animals, causes lethal disease,
although typically less than 100% lethality in mice (Warren
et al., 2014). We selected four of the mAbs among those with
the lowest in vitro neutralization IC50 values: MR72, MR82,
MR213, and MR232. The IC50 values in neutralization assays
with MARV Uganda or mouse-adapted MARV strain Ci67 were
comparable (within 2-fold). Seven-week-old BALB/c mice wereFebruary 26, 2015 ª2015 Elsevier Inc. 897
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Figure 4. Breadth of Binding or Neutralization of Human MARV-Specific mAbs for Diverse Filoviruses
(A) A heatmap showing the binding in ELISA of neutralizing mAbs from binding group 3B to the MARV and EBOV GPs. EC50 value for each antigen-mAb
combination is shown, with dark red shading indicating lower EC50 values and orange or yellow shading indicating intermediate or higher EC50 values. EC50 values
greater than 1,000 mg/ml are indicated by >.
(B) A heatmap showing the neutralization breadth of mAbs from binding group 3B. The IC50 value for each virus-mAb combination is shown, with dark red
shading indicating increased potency and orange or yellow shading indicating intermediate or low potency. IC50 values greater than 1,000 mg/ml are indicated
by >. Neutralization assays were performed in triplicate.injected with 100 mg of antibody by the IP route and challenged
with 1,000 plaque-forming unit (PFU) of Ci67. Twenty-four hours
later, antibody treatment was repeated. By day 6, all five control
(untreated) mice developed progressive loss of weight and
symptoms of the disease, including dyspnea, recumbency,
and unresponsiveness, and on days 8 and 9, two animals were
found dead and one animal was foundmoribund and euthanized.
The remaining two animals demonstrated recovery by day 11. In
contrast, all animals treated with any antibody survived and did
not display the elevation of the disease score, with the exception
of two animals treated with MR72, which showed a transient
marginal loss of weight and increase of the disease score on
days 6–9, which did not exceed 1 (Figure 5). The observed level
of protection was remarkable given the relatively modest in-
vitro-neutralizing potency of the antibodies.
DISCUSSION
There is an obvious urgent need for prophylactic and therapeutic
interventions for filovirus infections given the recurrence of
MARV outbreaks, including that in Uganda in October 2014
and a massive outbreak of EBOV infections in West Africa
in 2014. There is very little information about the structural
determinants of neutralization on which to base the rational
selection of antibodies, and for MARV there have been no re-
ported human nAbs.
This study reveals that naturally occurring human MARV nAbs
isolated from the B cells of a recovered donor principally target
the MARV NPC1 protein receptor-binding site, suggesting that
a major mechanism of MARV neutralization could be inhibition
of binding to receptor. Remarkably, some of the isolated anti-898 Cell 160, 893–903, February 26, 2015 ª2015 Elsevier Inc.bodies also bound to the EBOV GP. This mechanism of MARV
neutralization was unexpected, because previous studies with
EBOV showed that the putative receptor-binding domain on
GP is obscured on the surface of virions by the presence of the
glycan cap and mucin-like domain, only becoming exposed
following cleavage by cathepsin in the endosome. These studies
suggest that the configuration of the MARV GP differs signifi-
cantly from that of EBOV GP because the receptor-binding
domain must be accessible for immune recognition on MARV
GP. Indeed, determination of the structure of the MARV GP
and structural analysis of the interaction of mAb MR78 with
MARV and EBOV GP molecules shows this to be the case (see
Hashiguchi et al., 2015).
The information obtained from these studies can be used to
inform development of new therapeutics and structure-based
vaccine designs against filoviruses. Furthermore, as these
nAbs are fully human and exhibit inhibitory activity, they might
be useful as a component of a prophylactic or therapeutic
approach for filovirus infection and disease. The challenge
studies using amurine model here show clear evidence of in vivo
activity and suggest additional preclinical studies in other spe-
cies, such as guinea pigs and macaques, are warranted. Their
ability to bind a broad range of MARV isolates indicates they
may offer detection of or efficacy against new viral strains yet
to emerge. Although some of these mAbs bind to certain forms
of EBOV GP, these antibodies are not likely to be effective
against natural Ebola infection because the EBOV receptor-
binding site is obscured on the viral surface. However, such
mAbsmight neutralize EBOV if they could be delivered to the en-
dosome, where the EBOV receptor-binding site is exposed
following GP cleavage.
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Figure 5. Survival and Clinical Overview of Mice Treated with MARV mAbs
(A–C) Groups of mice at five animals per group were injected with individual mAbs by the intraperitoneal route twice: 1 hr prior and 24 hr after MARV challenge at
100 mg per treatment. Untreated animals served as controls. (A) Kaplan-Meier survival curves. (B) Body weight. (C) Illness score.EXPERIMENTAL PROCEDURES
Donor
The donor was an otherwise healthy adult woman who contracted Marburg
virus (MARV) infection in 2008 following exposure to fruit bats in the Python
Cave in Queen Elizabeth National Park, Uganda. The donor’s clinical course
was documented previously (CDC, 2009). Peripheral blood from the donor
was obtained in 2012, four years after the illness, following informed consent.
The study was approved by the Vanderbilt University Institutional Review
Board.
Viruses
MARV strain 200702854 Uganda (MARV-Uganda) was isolated originally from
a subject designated ‘‘patient A’’ during the outbreak in Uganda in 2007 (CDC,
2009; Towner et al., 2009) and underwent four passages in Vero E6 cells.
MARV strain Musoke (MARV-Musoke) was isolated during the outbreak in
Kenya in 1980 (Smith et al., 1982) and passaged five times in Vero E6 cells.
MARV strain 200501379 Angola (MARV-Angola) was isolated during the
outbreak in Angola in 2005 (Towner et al., 2006) and passaged three times
in Vero E6 cells. MARV Ravn virus (Ravn) was isolated from a patient in 1987
in Kenya (Johnson et al., 1996) and passaged four times in Vero E6 cells. All
strains of MARV were obtained originally from the Special Pathogens Branch,
U.S. Centers for Disease Control (CDC), and deposited at theWorld Reference
Center of Emerging Viruses and Arboviruses (WRCEVA) housed at UTMB. The
recombinant Ebola Zaire strain Mayinga (EBOV) expressing eGFP was gener-
ated in our laboratory by reverse genetics (Lubaki et al., 2013; Towner et al.,
2005) from plasmids provided by the Special Pathogens Branch at CDC and
passaged three times in Vero E6 cells. For analysis of antibody binding by
ELISA, viruses were gamma-irradiated with the dose of 5 3 106 rad. The re-
combinant VSV in which the VSV/GP protein was replaced with that of
MARV strain Musoke (VSV/GP-Musoke) or EBOV strain Mayinga (Garbutt
et al., 2004) were provided by Dr. Thomas Geisbert (UTMB) and Dr. Heinz
Feldmann (NIH), respectively; a similar virus with GP from MARV (strain200702854 Uganda) was constructed as described below. All work with
EBOV and MARV was performed within the Galveston National Laboratory
BSL-4 laboratories.
We used a mouse-adapted strain of MARV for testing the effect of mAbs
in vivo. The mouse-adapted Ci67 strain of Marburg virus (Warfield et al.,
2007) was provided by Dr. Sina Bavari (U.S. Army Medical Research Institute
of Infectious Diseases) and amplified by a single passage in Vero-E6 cells.
Generation of a Chimeric Strain of VSV in which VSV G Protein Was
Replaced with the GP Protein of MARV Strain Uganda
The plasmid pVSV-XN2 carrying cDNA of the full-length VSV anti-genome
sequence and the support plasmids pBS-N, pBS-L, and pBS-P encoding
the internal VSV proteins under control of the T7 promoter were kindly pro-
vided by Dr. John Rose (Yale University). The plasmid pC-T7, encoding the
T7 polymerase, was kindly provided by Dr. Yoshihiro Kawaoka (University of
Wisconsin). For generation of the VSV/GP-Uganda construct, Vero E6 cell
monolayers were inoculated with MARV strain 200702854, and total cellular
RNA was isolated and reverse transcribed. MARV GP open reading frame
(ORF) was PCR amplified from cDNA using forward primer 50-CATGTACG
ACGCGTCAACATGAGGACTA-30 and reverse primer 50-TCTAGCAGCTC
GAGCTATCCAATATATTTAGTAAAGATACGACAA-30 (MluI and XhoI endonu-
clease sites are underlined, respectively; the start and end of MARV GP ORF
direct and complementary sequences are italicized, respectively). To replace
VSV G with MARV GP, the resulting PCR product was cloned into pVSV-
XN2 using the unique MluI and XhoI endonuclease sites located between
the VSV G gene-start and gene-end signals and flanking its ORF, resulting in
the plasmid pVSV/GP-Uganda. To recover the recombinant virus, 1 3 106
BSR-T7 cells, kindly provided by Dr. Ursula Buchholz (U.S. National Institute
of Allergy and Infectious Diseases), were transfected with the following plas-
mids: pVSV/GP-Uganda, 5 mg, pBS-N, 1.5 mg, pBS-P, 2.5 mg, pBS-L, 1 mg,
and pC-T7, 5 mg. After 48 hr, transfected BSR-T7 cells were collected with a
cell scraper and transferred, along with the supernates, to Vero E6 cell mono-
layers for amplification of the recovered VSV/GP-Uganda.Cell 160, 893–903, February 26, 2015 ª2015 Elsevier Inc. 899
Generation of Human Hybridomas Secreting Monoclonal Antibodies
Peripheral blood mononuclear cells (PBMCs) from the donor were isolated
with Ficoll-Histopaque by density gradient centrifugation. The cells were cry-
opreserved immediately and stored in the vapor phase of liquid nitrogen until
use. Previously cryopreserved samples were thawed, and ten million PBMCs
were plated into 384-well plates (Nunc #164688) using 17 ml of cell culture
medium (ClonaCell-HY Medium A, StemCell Technologies, #03801), 8 mg/ml
of the TLR agonist CpG (phosphorothioate-modified oligodeoxynucleotide
ZOEZOEZZZZZOEEZOEZZZT, Invitrogen), 3 mg/ml of the Chk2 inhibitor
(Sigma #C3742), 1 mg/ml of cyclosporine A (Sigma #C1832), and 4.5 ml of clar-
ified supernate from cultures of B95.8 cells (ATCC VR-1492) containing
Epstein-Barr virus (EBV). After 7 days, cells from each 384-well culture plate
were expanded into four 96-well culture plates (Falcon #353072) using cell cul-
ture medium containing 8 mg/ml CpG, 3 mg/ml Chk2i, and ten million irradiated
heterologous human PBMCs (Nashville Red Cross) and incubated for an addi-
tional 4 days. Plates were screened for MARV antigen-specific antibody-
secreting cell lines using ELISAs. Cells from wells with supernates reacting
in a MARV antigen ELISA were fused with HMMA2.5 myeloma cells using an
established electrofusion technique (Yu et al., 2008). After fusion, hybridomas
were resuspended in medium containing 100 mM hypoxanthine, 0.4 mM
aminopterin, 16 mM thymidine (HAT Media Supplement, Sigma #HO262),
and 7 mg/ml ouabain (Sigma #O3125) and incubated for 18 days before
screening hybridomas for antibody production by ELISA.
Human mAb and Fab Production and Purification
After fusion with HMMA2.5 myeloma cells, hybridomas producing MARV-spe-
cific antibodies were cloned biologically by two rounds of limiting dilution and
by single-cell fluorescence-activated cell sorting. After cloning, hybridomas
were expanded in post-fusion medium (ClonaCell-HY Medium E, STEMCELL
Technologies #03805) until 50% confluent in 75-cm2 flasks (Corning #430641).
For antibody production, cells from one 75-cm2 flask were collected with a cell
scraper and expanded to four 225-cm2 flasks (Corning #431082) in serum-free
medium (Hybridoma-SFM, GIBCO #12045-076). After 21 days, supernates
were clarified by centrifugation and sterile filtered using 0.2-mm pore size filter
devices. HiTrap Protein G or HiTrap MabSelectSure columns (GE Healthcare
Life Sciences #17040501 and #11003494, respectively) were used to purify
antibodies from filtered supernates. Fab fragments were generated by
papain digestion (Pierce Fab Preparation Kit, Thermo Scientific #44985) and
purified by chromatography using a two-column system in which the first
column contained protein G resin (GE Healthcare Life Sciences #29048581)
and the second column contained either anti-kappa or anti-lambda antibody
light chain resins (GE Healthcare Life Sciences #17545811 and #17548211,
respectively).
Expression and Purification of MARV and EBOV GPs
Angola strain MARV GP ectodomains, containing the mucin-like domain
(MARV GP) or lacking residues 257–425 of the mucin-like domain (MARV
GPDmuc), were used to screen supernates of transformed B cells and human
hybridomas separately. Recombinant proteins for Ravn strain cleaved GP,
EBOVMayinga strain GP, EBOVMayinga strain GPDmuc, and EBOVMayinga
strain cleaved GP were designed and expressed similarly. Large-scale pro-
duction of recombinant GP or GPDmuc was performed by transfection of
Drosophila Schneider 2 (S2) cells with modified pMTpuro vectors, followed
by stable selection of transfected cells with 6 mg/ml puromycin. Secreted GP
ectodomain expression was induced with 0.5 mM CuSO4 for 4 days. Proteins
were engineered with a modified double strep tag at the C terminus (enteroki-
nase cleavage site followed by a strep tag/linker/strep tag) to facilitate purifi-
cation using Strep-Tactin resin (QIAGEN #2-1201). Proteins were purified
further by Superdex 200 size-exclusion chromatography in 10 mM Tris and
150 mM NaCl (pH 7.5) (13 TBS).
Lysates of MARV-Infected Cells
Lysates were prepared as previously described (Ksiazek et al., 1999). Briefly,
Vero E6 cell monolayers in 850 cm2 roller bottles were inoculated with approx-
imately 106 PFUMARV or EBOV and incubated at 37C until partial destruction
of monolayer occurred (approximately 9–10 days). Cell monolayers were de-
tached using 3-mm glass beads, and cell suspensions were centrifuged at900 Cell 160, 893–903, February 26, 2015 ª2015 Elsevier Inc.16,0003 g for 10 min at 4C. Supernates were discarded; cell pellets were re-
suspended in 103 excess of borate buffer saline (10mMNa2B4O7 and 150mM
NaCl [pH 9.0]) and centrifuged at 16,000 3 g for 10 min at 4C. Supernates
were discarded; cell pellets were resuspended in cold 1% Triton X-100 (Fisher
Scientific) in borate buffer saline, vortexed, and gamma-irradiated on dry ice at
53 106 rad. The lysates were sonicated with a 600 W Tekmar Sonic Disruptor
TM600 (Tekmar) using a cuphorn sonicator at maximum power setting and
50% duty cycle for 10 min and centrifuged at 16,000 3 g, and the supernates
were aliquoted.
Screening ELISA
ELISA plates were coated with lysates of MARV-infected cells (diluted 1:1,000
in Dulbecco’s PBS [DPBS]) or recombinant MARV GP or MARV GPDmuc pro-
teins (20 mg in 10 ml DPBS per plate) and incubated at 4C overnight. Plates
were blocked with 100 ml of blocking solution/well for 1 hr. Blocking solution
consisted of 10 g powdered milk, 10 ml of goat serum, 100 ml of 103
DPBS, and 0.5 ml of Tween-20 mixed to a 1 l final volume with distilled water.
The presence of antibodies bound to the GP was determined using goat anti-
human immunoglobulin G (IgG) horseradish peroxidase-conjugated second-
ary antibodies (Southern Biotech #2040-05, 1:4,000 dilution) and 1-Step Ultra
TMB-ELISA substrate (Thermo Scientific #34029), with optical density read at
450 nM after stopping the reaction with 1M HCl.
Half-Maximal Effective Concentration Binding Analysis
MARV or EBOV GPs, MARV or EBOV GPDmuc, or Ravn or EBOV cathepsin-
cleaved GPs were coated onto 384-well plates (Thermo Scientific Nunc
#265203) in DPBS at 2 mg/ml overnight, then antigen was removed, and plates
were blocked with blocking solution made as above. Antibodies were applied
to the plates at a concentration range of 1.5 mg/ml to 270 ng/ml (binding
groups #1, #2, and 3A) and 0.1 mg/ml to 10 ng/ml (binding group #3B) using
3-fold serial dilutions. The presence of antibodies bound to the GP was deter-
mined using goat anti-human IgG alkaline phosphatase conjugate (Meridian
Life Science #W99008A, 1:4,000 dilution) and p-nitrophenol phosphate sub-
strate tablets (Sigma #S0942), with optical density read at 405 nM after
120 min. A non-linear regression analysis was performed on the resulting
curves using Prism (v. 5) (GraphPad) to calculate EC50 values.
MARV and EBOV Neutralization Experiments
Dilutions of mAbs in triplicate were mixed with 150 PFU of MARV or EBOV
expressing eGFP in MEM containing 10% fetal bovine serum (FBS) (HyClone)
and 50 mg/ml gentamicin (Cellgro #30-005-CR) with or without 5% guinea
pig complement (MP Biomedicals #642836) in a total volume of 0.1 ml
and incubated for 1 hr at 37C for virus neutralization. Following neutralization,
virus-antibody mixtures were placed on monolayers of Vero E6 cells in 24-well
plates, incubated for 1 hr at 37C for virus adsorption, and overlayedwithMEM
containing 2% FBS and 0.8% methylcellulose (Sigma-Aldrich #M0512). After
incubation for 5 days, medium was removed, cells were fixed with 10%
formalin (Fisher Scientific #245-684), and plates were sealed in plastic bags
and incubated for 24 hr at room temperature. Sealed plates were taken out
of the BSL-4 laboratory according to approved SOPs, and monolayers were
washed three times with PBS. Viral plaques were immunostained with the
serum of rabbits that had been hyperimmunized with MARV, or with a mAb
against EBOV, clone 15H10 (BEI Resources #NR-12184). Alternatively,
following virus adsorption, monolayers were covered with MEM containing
10% FBS and 1.6% tragacanth (Sigma-Aldrich #G1128). After incubation for
14 days, medium was removed, cells were fixed with 10% formalin, and plates
were sealed in plastic bags, incubated for 24 hr at room temperature, and
taken out of the BSL-4 laboratory as above. Fixed monolayers were stained
with 10% formalin containing 0.25% crystal violet (Fisher Scientific #C581-
100), and plaques were counted.
VSV-MARV and VSV-EBOV Neutralization Tests
Neutralization assays were performed in triplicate, as described above for
MARV and EBOV. Following neutralization, virus-antibody mixtures were
placed on monolayers of Vero E6 cells in duplicate, incubated for 1 hr at
37C for virus adsorption, and overlayed with MEM containing 2% FBS con-
taining 0.9% methylcellulose. After incubation for 3 days, medium was
removed, monolayers were fixed and stained with 10% formalin containing
0.25% crystal violet, and plaques were counted.
Generation and Sequencing of VSV/GP-Uganda Escape Mutants
Vero E6 cell monolayers with 2-fold dilutions of mAbs (12.5–200 mg/ml) added
to the medium were inoculated with 200 PFU of recombinant VSV/GP-Uganda
and incubated at 37C for 2–4 days. To determine which samples contained
live virus, supernates were collected, virus was titrated in Vero E6 cell mono-
layers under methylcellulose overlay, monolayers were incubated at 37C for
3–4 days, and plaques were counted. Supernates with the highest concentra-
tions of mAbs, which were found to contain live virus by plaque titration, were
incubated in presence of serially diluted mAbs, followed by titration of virus as
above. The procedure was performed a total of three times. Escape mutant
viruses harvested after the third passage were cloned biologically by plaque
purification. For biological cloning, Vero E6 cell monolayers in 24-well plates
were inoculated with dilutions of the escape mutant viruses in the presence
of the corresponding mAbs (200 mg/ml of MR72 or 100 mg/ml of MR78) and
covered with 0.7% low melting temperature SeaPlaque agarose (Lonza
#50100). Monolayers were incubated at 37C for 6 days; plaques were visual-
ized with 0.01% neutral red aqueous solution (Electron Microscopy Sciences),
picked, resuspended in medium, and transferred to Vero E6 cell monolayers in
24-well plates in the presence of the corresponding mAbs (200 mg/ml of MR72
or 100 mg/ml of MR78) for virus propagation. In 2–5 days, based on the extent
of CPE observed, virus was harvested, and cells were dissolved in Trizol re-
agent (Life Technologies 315596018). Total cellular RNA was extracted,
reverse transcribed, and amplified by PCR with the primers described above
for generation of a chimeric strain of VSV. Two overlapping fragments
covering MARV GP ORF were PCR amplified from cDNA using forward primer
50-CATGTACGACGCGTCAACATGAGGACTA-30 and reverse primer 50-ACT
AAGCCCTGCTGCCAGGT-30 or forward primer 50-ACAACAATGTACCGAGG
CAA-30 and reverse primer 50-TCTAGCAGCTCGAGCTATCCAATATATTTAG
TAAAGATACGACAA-30, and the nucleotide sequences of the GP ORFs
were determined using standard procedures.
Analysis of Growth Kinetics of VSV/GP-Uganda Escape Mutant
Viruses
Vero E6 cell monolayers in 24-well plates were inoculated in triplicate with
VSV/GP-Uganda escape mutants or non-mutated virus at an MOI of
0.00025 PFU/cell in the presence of varying concentrations of the correspond-
ing mAbs. Aliquots of medium were collected every 12 hr and frozen for titra-
tion at a later time. Titration of virus in aliquots was performed as above,
without adding antibodies to the culture medium.
Biolayer Interferometry Competition Binding Assay
Biotinylated GP or GPDmuc (EZ-link Micro NHS-PEG4-Biotinylation Kit,
Thermo Scientific #21955) (1 mg/ml) was immobilized onto streptavidin-coated
biosensor tips (ForteBio #18-5019) for 2 min. After measuring the baseline
signal in kinetics buffer (KB; 13 PBS, 0.01% BSA, and 0.002% Tween 20)
for 2 min, biosensor tips were immersed into the wells containing primary anti-
body at a concentration of 100 mg/ml for 10 min. Biosensors then were
immersed into wells containing competing mAbs at a concentration of
100 mg/ml for 5min. The percent binding of the competingmAb in the presence
of the first mAb was determined by comparing the maximal signal of
competing mAb applied after the first mAb complex to the maximal signal of
competing mAb alone. MAbs were judged to compete for binding to the
same site if maximum binding of the competing mAb was reduced to <30%
of its un-competed binding. MAbs were considered non-competing if
maximum binding of the competing mAb was >70% of its un-competed bind-
ing. A level of 30%–70% of its un-competed binding was considered interme-
diate competition.
Sequence Analysis of Antibody Variable Region Genes
Total cellular RNAwas extracted from clonal hybridomas that producedMARV
antibodies, andRT-PCR reaction was performed usingmixtures of primers de-
signed to amplify all heavy-chain or light-chain antibody variable regions. The
generated PCR products were purified and cloned into the pJet 1.2 plasmid
vector (Thermo Scientific, #K1231) for sequence analysis. The nucleotide se-quences of plasmid DNAs were determined using an ABI3700 automated
DNA sequencer. Heavy-chain or light-chain antibody variable region se-
quences were analyzed using the IMGT/V-Quest program (Brochet et al.,
2008; Giudicelli et al., 2011). The analysis involved the identification of germline
genes that were used for antibody production, location of complementary
determining regions (CDRs), and framework regions (FRs), as well as the num-
ber and location of somatic mutations that occurred during affinity maturation.
Statistical Analysis
EC50 values for neutralization were determined by finding the concentration of
mAb at which a 50% reduction in plaque counts occurred after incubation of
virus with neutralizing antibody. A logistic curve was fit to the data using the
count as the outcome and the log-concentration as the predictor variable.
The results of the model then were transformed back to the concentration
scale. Results are presented as the concentration at the dilution that achieves
a 50% reduction from challenge control with accompanying 95% confidence
intervals. Each antibody was treated as a distinct analysis in a Bayesian non-
linear regression model.
Sample Preparation for EM Studies
A Ravn strain MARV GPmucin-deleted construct (GPDmuc) was produced by
stable cell line expression in Drosophila S2 cells, as described above. Human
Fab proteins for MARV-specific antibodies were generated as described
above. Fabs were added in molar excess to GPDmuc and allowed to incubate
overnight at 4C. Complexes then were purified by Superdex 200 size-exclu-
sion chromatography in TBS.
Electron Microscopy and Sample Preparation
A 4 ml aliquot of each complex that had been diluted to a concentration
of 0.03 mg/ml with TBS buffer was placed for 15 s onto carbon-coated
400 Cu mesh grids that had been plasma cleaned for 20 s (Gatan), blotted
off on the edge of the grid, and then immediately stained for 30 s with 4 ml of
2% uranyl formate. The stain was blotted off on the edge of the grid, and the
grid was allowed to dry. Data were automatically collected with Leginon (Car-
ragher et al., 2000; Potter et al., 1999; Suloway et al., 2005) using a FEI Tecnai
F20 electron microscope operating at 120 keV with an electron dose of
30 e/A˚2 and a magnification of 52,0003 that resulted in a pixel size of
2.65 A˚ at the specimen plane when collected with Tietz CMOS 4k 3 4k CCD
camera. Particle orientations appeared to be generally isotropic, and images
were acquired at a constant defocus value of 1.0 mm at 0 stage tilt.
Image Processing of Protein Complexes
Particles were picked automatically using DoG Picker (34) and placed into a
particle stack using the Appion software (Lander et al., 2009). Reference-
free 2D class averages were generatedwith the Xmipp clustering 2D alignment
software (van Heel et al., 1996) and sorted into an initial 300 classes. Non-GP
particles were removed, and the stack was further subclassified into classes
with 100 particles per class in order to generate the final particle stack
used for the reconstruction. Various numbers of class averages were chosen
to create initial models using EMAN2 common lines software (Tang et al.,
2007). A model that best matched its projected classes was then used for
refinement against the raw particle stack, imposing C3 symmetry, and the
reconstruction was generated with ten rounds of refinement and increasingly
smaller angular sampling rates with EMAN2 (Tang et al., 2007). All model fitting
andmanipulation was completed using UCSF Chimera (Pettersen et al., 2004).
In Vivo Testing
The animal protocol for testing of mAbs in mice was approved by the Institu-
tional Animal Care and Use Committee of the University of Texas Medical
Branch at Galveston. Seven-week-old BALB/c mice (Harlan) were placed in
the ABSL-4 facility of the Galveston National Laboratory. Groups of mice at
five animals per group were injected with individual mAbs by the intraperito-
neal route twice: 1 hr prior and 24 hr after MARV challenge, using 100 mg
per treatment. Untreated animals served as controls. For the challenge,
mice were injected with 1,000 PFU of the mouse-adapted MARV strain Ci67
by the intraperitoneal route. Animals were weighed and monitored daily over
the 3-week period after challenge. Once animals were symptomatic, theyCell 160, 893–903, February 26, 2015 ª2015 Elsevier Inc. 901
were examined twice per day. The disease was scored using the following
parameters: dyspnea (possible scores 0–5), recumbency (0–9), unresponsive-
ness (0–5), and bleeding/hemorrhage (0–5); the individual scores for each
animal were summarized.
ACCESSION NUMBERS
EM reconstructions have been deposited in the Electron Microscopy Data
Bank under the accession codes EMD-6232 through 6238.
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